2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

human peripheral blood mononuclear cell

" in MedChemExpress (MCE) Product Catalog:

69

Inhibitors & Agonists

1

Fluorescent Dyes

2

Biochemical Assay Reagents

1

Peptides

4

MCE Kits

14

Inhibitory Antibodies

2

Natural
Products

1

Click Chemistry

4

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-150096
    Zasocitinib
    1 Publications Verification

    NDI-034858; TAK-279

    		 JAK Inflammation/Immunology
    Zasocitinib (NDI-034858) is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM .
    Zasocitinib
  • HY-P990876
    Afimkibart

    PF-06480605; RVT-3101

    		 TNF Receptor NF-κB IFNAR Inflammation/Immunology
    Afimkibart (PF-06480605; RVT-3101) is a fully human monoclonal antibody that selectively inhibits trimeric tumor necrosis factor-like ligand 1A (TL1A). Afimkibart neutralizes active trimeric TL1A, blocks TL1A-induced signaling pathways. Afimkibart inhibits NF-κB activation and IFN-γ production. Afimkibart can be used for the research of inflammatory bowel disease .
    Afimkibart
  • HY-P991028
    Surovatamig

    AZD0486; TNB-486

    		 CD3 CD19 Interleukin Related TNF Receptor IFNAR Cancer
    Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma .
    Surovatamig
  • HY-132248
    C5 Lenalidomide

    Lenalidomide 5'-amine

    		 Drug Derivative TNF Receptor Inflammation/Immunology
    C5 Lenalidomide is a 5-amino-substituted Thalidomide (HY-14658) analog. C5 Lenalidomide inhibits LPS (HY-D1056)-stimulated TNF-α production .
    C5 Lenalidomide
  • HY-138568
    HPK1-IN-3

    		MAP4K Inflammation/Immunology
    HPK1-IN-3 is a potent and selective ATP-competitive hematopoietic progenitor kinase 1 (HPK1; MAP4K1) inhibitor with an IC50 of 0.25 nM. HPK1-IN-3 has IL-2 cellular potency with an EC50 of 108 nM in human peripheral blood mononuclear cells (PBMCs) .
    HPK1-IN-3
  • HY-B2162C
    Chondroitin sulfate (from pig)

    Chondroitin polysulfate (from pig)

    		 Endogenous Metabolite Inflammation/Immunology
    Chondroitin sulfate (from pig) (Chondroitin polysulfate (from pig)) is a sulfated linear polysaccharide extracted from pigs, which belongs to glycosaminoglycans. Chondroitin sulfate (from pig) exerts inconsistent inhibitory effects on the resorptive activity of human osteoclasts. Chondroitin sulfate (from pig) can be used in studies related to osteoarthritis .
    Chondroitin sulfate (from pig)
  • HY-177338
    STING agonist-45

    		STING Cyclic GMP-AMP Synthase IFNAR TNF Receptor Interleukin Related Inflammation/Immunology Cancer
    STING agonist-45 is a selective STING agonist (EC50 = 0.28 μM). STING agonist-45 activates the innate immune response through the cGAS-STING pathway, upregulating key markers such as p-TBK1 and IRF3. STING agonist-45 exhibits robust STING activation in human peripheral blood mononuclear cells (PBMCs), inducing the production of type I interferons (such as IFN-β) and downstream cytokines (such as TNF-α and IL-6). STING agonist-45 enhances anti-tumor immunity, inhibits tumor growth, and increases CD8 + T cell infiltration in mouse models. STING agonist-45 is promising for the study of STING-related diseases .
    STING agonist-45
  • HY-155175
    TIM-3-IN-2

    		Tim3 IFNAR Cancer
    TIM-3-IN-2 is a TIM-3 inhibitor. TIM-3-IN-2 blocks the interactions of TIM-3 with PtdSer, CEACAM1 and Gal-9, and inhibits the immunosuppressive function of TIM-3. TIM-3-IN-2 restores IFNγ release from peripheral blood mononuclear cells. TIM-3-IN-2 inhibits the proliferation of acute myeloid leukemia cells. TIM-3-IN-2 can be used for the research of acute myeloid leukemia .
    TIM-3-IN-2
  • HY-153068
    CZL55

    		Caspase Neurological Disease
    CZL55 is a caspase-1 inhibitor. CZL55 can be used for the research of febrile seizures (FS) .
    CZL55
  • HY-N7066
    Difloxacin hydrochloride

    A-56619 hydrochloride

    		 Bacterial DNA/RNA Synthesis Infection
    Difloxacin hydrochloride (A-56619 hydrochloride) is an orally active bactericidal agent. Difloxacin hydrochloride inhibits bacterial DNA gyrase. Difloxacin hydrochloride exhibits concentration-dependent bactericidal activity. Difloxacin hydrochloride shows strong in vitro activity against a variety of Gram-positive and Gram-negative bacteria. Difloxacin hydrochloride can be used in research related to colibacillosis and *Staphylococcus aureus* infections .
    Difloxacin hydrochloride
  • HY-156961
    Cadefrecitinib

    GLPG3667

    		 JAK Inflammation/Immunology
    Cadefrecitinib (GLPG3667) is a reversible, ATP-competitive and orally active TYK2 inhibitor with an IC50 of 2.3 nM. Cadefrecitinib inhibits IFNα/pSTAT1, and the IC50 values ​​in human peripheral blood mononuclear cell (PBMC) and whole blood assays are 70 nM and 623 nM, respectively. Cadefrecitinib has the potential for the study of inflammatory and autoimmune diseases .
    Cadefrecitinib
  • HY-145885
    TLR7/8 agonist 6

    		Toll-like Receptor (TLR) TNF Receptor Interleukin Related IFNAR Infection Inflammation/Immunology Cancer
    TLR7/8 agonist 6 is a TLR7/8 agonist with EC50s of 0.18 μM and 5.34 μM in TLR7 or TLR8 HEK-SEAP reporter cells, respectively. TLR7/8 agonist 6 potently stimulates production of TNFα, IFNγ, and IL-1β. TLR7/8 agonist 6 can be used for research on cancer and infectious diseases .
    TLR7/8 agonist 6
  • HY-P991257
    MK-1966
    1 Publications Verification

    		 Interleukin Related CXCR MHC Cancer
    MK-1966 is an anti-IL-10 antibody. MK-1966 inhibits secretion of cytokines from activated macrophages, production of CC and CXC chemokines, and a TH1 response, down-regulates MHC and costimulatory molecules on dendritic cells (DCs), and induces regulatory T cells. MK-1966 can be used for the research of cancer , such as gastric cancer .
    MK-1966
  • HY-P991201
    REGN-7257

    		Interleukin Related Inflammation/Immunology
    REGN-7257 is a humanized monoclonal antibody targeting IL2RG. REGN-7257 blocks the signal transduction induced by common gamma chain (γc) cytokines via the IL2RG chain of the γc cytokine receptor complex. REGN-7257 is applicable for research on immune-mediated diseases and T cell-mediated diseases . Its corresponding isotype control is Human IgG4 kappa, Isotype Control (HY-P99003).
    REGN-7257
  • HY-142989
    1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine

    		Liposome HIV HCV HBV Infection Cancer
    1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is a polyunsaturated phospholipid that serves as a component of lipid monolayers and small unilamellar vesicles. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine can be used to prepare endoplasmic reticulum-targeted liposomes (PERLs), which are composed of 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, l-α-phosphatidylinositol and l-α-phosphatidylserine at a molar ratio of 1.5:1.5:1:1. PERLs reduce cholesterol levels in human peripheral blood mononuclear cells (PBMCs) and decrease HIV-1 particle secretion from HIV-1-infected PBMCs. Liposomes formed from 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine exhibit cytotoxicity against leukemia cells. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is applicable to studies related to hepatitis C virus infection, HIV infection, hepatitis B virus infection and leukemia .
    1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine
  • HY-106850
    3′-Azido-2′,3′-dideoxyuridine

    AzdU; AzddU; CS-87

    		 HIV Infection
    3′-Azido-2′,3′-dideoxyuridine (AzdU) is a nucleoside analog of Zidovudine (HY-17413). 3′-Azido-2′,3′-dideoxyuridine is a potent inhibitor of human immunodeficiency virus (HIV) replication in human peripheral blood mononuclear cells (PBMC) with limited toxicity for human bone marrow cells (BMC) . 3′-Azido-2′,3′-dideoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    3′-Azido-2′,3′-dideoxyuridine
  • HY-148511
    Vidutolimod

    CMP-001

    		 Toll-like Receptor (TLR) IFNAR PD-1/PD-L1 Indoleamine 2,3-Dioxygenase (IDO) Cancer
    Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .
    Vidutolimod
  • HY-P990090
    Rademikibart

    CBP-201

    		 Interleukin Related STAT Inflammation/Immunology
    Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα and IL-4Rα inhibitor with a KD of 20.7 pM when binding to human IL-4Rα epitopes . Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and thymus activation regulated chemokine (TRAC) production. Rademikibart can be used for the research of atopic dermatitis and asthma .
    Rademikibart
  • HY-178037
    TLR9 antagonist 1

    		Toll-like Receptor (TLR) Interleukin Related TNF Receptor Inflammation/Immunology
    TLR9 antagonist 1 is a selective hTLR9 antagonist with an IC50 of 0.1 nM against hTLR9. TLR9 antagonist 1 exhibits favorable pharmacokinetic and pharmacodynamic properties. TLR9 antagonist 1 can be used in the research of systemic lupus erythematosus .
    TLR9 antagonist 1
  • HY-145886
    TLR7/8 antagonist 1

    		Toll-like Receptor (TLR) Interleukin Related Infection Inflammation/Immunology Cancer
    TLR7/8 antagonist 1 (Compound 16c) is a competitive TLR7/8 antagonist with IC50 values of 3.91 μM and 2.19 μM, respectively. TLR7/8 antagonist 1 reduces agonist-induced production of proinflammatory cytokines, including TNFα, IFNγ and IL-1β .
    TLR7/8 antagonist 1
  • HY-156065
    S217879

    		Keap1-Nrf2 Reactive Oxygen Species (ROS) Interleukin Related Metabolic Disease
    S217879 is an orally active and selective NRF2 activator. S217879 activates the NRF2 pathway by specifically disrupting the KEAP1 (Kd: 4.15 nM)-NRF2 interaction, and upregulates the antioxidant response. S217879 also ameliorates steatohepatitis and reduces the degree of liver fibrosis. S217879 can be used in the research of metabolic dysfunction-associated steatotic liver disease and nonalcoholic steatohepatitis .
    S217879
  • HY-P4984
    Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78)

    		Biochemical Assay Reagents Inflammation/Immunology Cancer
    Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) is a T cell proliferation activator. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) promotes the in vitro proliferation of human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) can be used in research on inflammatory and immunity, as well as cancer .
    Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78)
  • HY-176192
    SMU-14a

    		Toll-like Receptor (TLR) NF-κB p38 MAPK ERK IKK TNF Receptor Interleukin Related Inflammation/Immunology
    SMU-14a is a selective Toll-like receptor 3 (TLR3) inhibitor wirh an IC50 of 0.18 μM. SMU-14a reduces phosphorylation of p65, ERK, and TBK1 via NF-κB, MAPK, and IRF3 signaling pathways. SMU-14a inhibits IL-6 secretion in mouse peritoneal macrophages, downregulates TNF-α in human peripheral blood monocytes and decreases serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. SMU-14a can be used for the research of acute hepatitis .
    SMU-14a
  • HY-150744A
    ODN 24888 sodium

    		Toll-like Receptor (TLR) Inflammation/Immunology
    ODN 24888 sodium is an guanine-modified inhibitory oligonucleotides (INH-ODN), shows potent inhibition on TLR7/TLR9-mediated signaling. ODN 24888 sodium impairs IFN-α level and NF-κB activation, inhibits IL-6 release. ODN 24888 sodium involves in immune and inflammatory responses, can be used as a vaccine adjuvant .
    ODN 24888 sodium
  • HY-179047
    SMU-L11-R

    		Toll-like Receptor (TLR) MyD88 IKK p38 MAPK ERK TNF Receptor Interleukin Related Inflammation/Immunology Cancer
    SMU-L11-R is a selective TLR7 agonist with an EC50 of 0.012 μM for human TLR7. SMU-L11-R specifically activates TLR7, recruits  MyD88, and triggers MAPK/NF-κB pathways, leading to TNF-α/IL-1β/IL-6 secretion in both mouse and human peripheral blood mononuclear cells. SMU-L11-R promotes M1-like macrophage polarization. SMU-L11-R exhibits excellent synergistic anti-tumor effects with PD-L1 inhibitors by upregulating CD8 +T cells. SMU-L11-R shows potential in colorectal cancer studies .
    SMU-L11-R
  • HY-118917
    VX-148

    		IMPDH Inflammation/Immunology
    VX-148 is an orally active immunosuppressant, which is a non-competitive inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor with Ki values for IMPDH Ⅱ and IMPDH Ⅰ of 6 and 14 nM respectively. VX-148 can significantly inhibit the proliferation of human peripheral blood mononuclear cells (PBMC) stimulated by T-cell mitogen (PHA) or B-cell mitogen (SPAS). VX-148 has high selectivity for lymphocytes (such as L1210, Jurkat T cells, and Raji B cells), but has no significant toxicity to non-lymphoid cells. VX-148 can inhibit antibody responses in mouse models and significantly prolong the survival time of transplanted skin in allogeneic skin transplantation models. VX-148 can be used in the research of autoimmune diseases (such as rheumatoid arthritis, psoriasis) and organ transplantation anti-rejection .
    VX-148
  • HY-127023
    Eicosapentaenoyl serotonin

    EPA-5-HT

    		 Endogenous Metabolite FAAH Interleukin Related Tyrosine Hydroxylase Metabolic Disease
    Eicosapentaenoyl serotonin (EPA-5-HT) is an endogenous fatty acid-serotonin conjugate lipid mediator. Eicosapentaenoyl serotonin acts as an inhibitor of fatty acid amide hydrolase (FAAH). Eicosapentaenoyl serotonin suppresses IL-17 release in Concanavalin A (HY-P2149)-stimulated human peripheral blood mononuclear cells. Eicosapentaenoyl serotonin is regulated by polyunsaturated fatty acids and modulates intestinal immunity and Th17 signaling. Eicosapentaenoyl serotonin can be used for the study of inflammatory bowel disease-related mechanisms .
    Eicosapentaenoyl serotonin
  • HY-N15307
    Trigraecum

    		Interleukin Related TNF Receptor Inflammation/Immunology
    Trigraecum is a flavonoid compound found in Dracaena steudneri and Dalbergia cochinchinensis, exhibiting anti-inflammatory activity. It can inhibit the LPS (HY-D1056)-induced production of IL-1β, IL-2, GM-CSF, and TNF-α in human peripheral blood mononuclear cells. Trigraecum holds promise for research on inflammatory diseases .
    Trigraecum
  • HY-150744
    ODN 24888

    		Toll-like Receptor (TLR) Inflammation/Immunology
    ODN 24888 is an guanine-modified inhibitory oligonucleotides (INH-ODN), shows potent inhibition on TLR7/TLR9-mediated signaling. ODN 24888 impairs IFN-α level and NF-κB activation, inhibits IL-6 release. ODN 24888 involves in immune and inflammatory responses, can be used as a vaccine adjuvant .
    ODN 24888
  • HY-177300
    TLR7/8 agonist 13

    		Toll-like Receptor (TLR) HBV IFNAR Interleukin Related Infection Inflammation/Immunology
    TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (lowest effective concentrations (LEC) [hTLR7] = 1.6 μM) and TLR8 (LEC [hTLR8] = 1.6 μM). TLR7/8 agonist 13 exhibits agonistic activity against human peripheral blood mononuclear cells (hPBMCs) (LEC [hPBMC] = 0.5 μM). TLR7/8 agonist 13 induces endogenous IFNα, activating myeloid dendritic cells and monocytes toward a TH1 phenotype in mice and cynomolgus monkeys. TLR7/8 agonist 13 reduces viral load and HBV surface antigen expression in a mouse model of chronic AAV-HBV infection. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, which may promote HBV antigen-specific CD8 T cell-mediated responses. TLR7/8 agonist 13 can be used to study hepatitis B virus .
    TLR7/8 agonist 13
  • HY-162845
    TLR7/8 agonist 11

    		Toll-like Receptor (TLR) Inflammation/Immunology
    TLR7/8 agonist 11 (compound 30) is a potent agonist of hTLR7 and hTLR8, with EC50s of 31.1 nM and 13.1 nM, respectively. TLR7/8 agonist 11 plays an important role in adaptive and innate immune responses .
    TLR7/8 agonist 11
  • HY-105207
    L 696229

    		HIV Infection
    L 696229 is a specific inhibitor ofhuman immunodeficiency virus type 1 (HIV-1)reverse transcriptase (RT) activity that possesses antiviral activity .
    L 696229
  • HY-112481
    IKK2-IN-5

    		Inflammation/Immunology
    IKK2-IN-5 is a selective IKK-2 inhibitor with an IC50 of 0.025 μM. IKK2-IN-5 inhibits the production of TNF-α in LPS (HY-D1056)-stimulated human peripheral blood mononuclear cells. IKK2-IN-5 exhibits extremely low cytotoxicity against human peripheral blood mononuclear cells .
    IKK2-IN-5
  • HY-153952
    Immuno modulator-1

    		TNF Receptor Interleukin Related Potassium Channel Inflammation/Immunology Cancer
    Immuno modulator-1 (compound 22) inhibits TNFα and IL-2 secretion in human peripheral blood mononuclear cells (hPBMC), with IC50 values of 4.7 and 26 nM, respectively. Immuno modulator-1 shows hERG potassium channel blocking effect, with Inhibitory percentage of 20% at 3 μM .
    Immuno modulator-1
  • HY-N6857R
    Armepavine (Standard)

    		Reference Standards NF-κB Inflammation/Immunology
    Armepavine (Standard) is the analytical standard of Armepavine. This product is intended for research and analytical applications. Armepavine, an active compound from Nelumbo nucifera, exerts not only anti-inflammatory effects on human peripheral blood mononuclear cells, but also immunosuppressive effects on T lymphocytes and on lupus nephritic mice. Armepavine inhibits TNF-α-induced MAPK and NF-κB signaling cascades .
    Armepavine (Standard)
  • HY-124954
    MN-25

    		Cannabinoid Receptor TNF Receptor Neurological Disease Inflammation/Immunology
    MN-25 (compound 4a) is an orally active indolpyridone that serves as a novel cannabinoid ligand. MN-25 has Ki of 245 nM and 11 nM for CB1 and CB2. MN-25 has CB2 agonist activity and inhibits TNF-R release in human peripheral blood mononuclear cells in vitro with an IC50 of 33 μM. MN-25 shows efficacy in a mouse acute inflammation model at oral doses up to 50 mg/kg >[1].
    MN-25
  • HY-122566
    SMU127

    ZINC666243

    		 Toll-like Receptor (TLR) TNF Receptor Cancer
    SMU127 is an agonist of the toll-like receptor 1/2 (TLR1/2) heterodimer. It induces NF-κB signaling in cells expressing human TLR2 (EC50=0.55 μM) but not cells expressing human TLR3, -4, -5, -7, or -8 when used at concentrations ranging from 0.1 to 100 μM. SMU127 induces the production of TNF-α in isolated human peripheral blood mononuclear cells (PBMCs) when used at concentrations ranging from 0.01 to 1 μM. In vivo, SMU127 (0.1 mg/animal) reduces tumor volume in a 4T1 murine mammary carcinoma model.
    SMU127
  • HY-19242
    MX-68

    		Antifolate Inflammation/Immunology
    MX-68 is an orally active antifolate agent. MX-68 can prolong the lifespan of MRL/lpr mice, delay the onset of proteinuria, and inhibit the elevation of serum blood urea nitrogen and cholesterol levels. MX-68 is also an anti-rheumatic agent, which exerts potent antiproliferative effects on rheumatoid arthritis-related cells and can inhibit arthritis in rats. MX-68 can be used in the research of autoimmune diseases such as autoimmune kidney disease and rheumatoid arthritis .
    MX-68
  • HY-168074
    4″-C18 EGCG

    		Amylases Glycosidase Metabolic Disease Inflammation/Immunology
    4″-C18 EGCG is a potent inhibitor of α-amylase and α-glucosidase with IC50 values of 3.74 and 0.81 μM, respectively. 4″-C18 EGCG inhibits carbohydrate hydrolases, reduces oxidative stress and inflammation, and exhibits antidiabetic activity. 4″-C18 EGCG also downregulates proinflammatory cytokines and is cytotoxic to primary human peripheral blood mononuclear cells (PBMCs), non-cancer cell lines 3T3-L1, and HEK 293 at 50 μM .
    4″-C18 EGCG
  • HY-P992040
    HAIL-12

    16G2

    		 Interleukin Related Others
    HAIL-12 (16G2) is anan anti-human Interleukin-12 (IL-12p70) monoclonal antibody. HAIL-12 inhibits IL-12-mediated proliferation of T cells from human peripheral blood mononuclear cells .
    HAIL-12
  • HY-168384
    M04

    		STING TNF Receptor Interleukin Related CD28 Inflammation/Immunology
    M04 is an agonist of STING. It induces the expression of the IFN reporter gene in HEK293T cells expressing wild-type human STING, but does not induce this expression in HEK293T cells expressing the R71H-G230A-R293Q (HAQ) STING variant or in mouse RAW 264.7 cells, indicating that its activity is dependent on allelic and species variations. M04 induces the production of TNF-α, IL-10, IL-1β, and IL-12p70 in human peripheral blood mononuclear cells (PBMCs). At a concentration of 50 µM, M04 stimulates dendritic cells isolated from PBMCs to express the MHC class II cell surface receptor HLA-DR and co-stimulatory molecules CD40, CD80, and CD86, and also enhances their ability to activate T cells in an ex vivo assay. M04 can be used in research on inflammatory immune diseases .
    M04
  • HY-180320
    Lu AF58786

    		LRRK2 Neurological Disease
    Lu AF58786 is a potent and selective LRRK2 inhibitor with an IC50 of 12 nM. Lu AF58786 also exhibits inhibition activity against LRRK2 G2019S and LRRK2 A2016T with IC50s of 19 and 93 nM. Lu AF58786 inhibits phosphorylation of LRRK2, Rab10 and Rab12 in human peripheral blood mononuclear cells. Lu AF58786 can be used for parkinson’s disease research .
    Lu AF58786
  • HY-181710
    LASSBio-2337

    		mTOR PI3K Cancer
    LASSBio-2337 is a dual pan-PI3K/mTOR inhibitor with an mTOR IC50 of 5.8 μM.LASSBio-2337 functionally modulates mTOR and all PI3K isoforms.LASSBio-2337 acts as a cytotoxic agent in leukemia cells, including multidrug-resistant populations.LASSBio-2337 spares nontumor human peripheral blood mononuclear cells.LASSBio-2337 displays moderate PAMPA-GIT permeability.LASSBio-2337 shows low metabolic stability in rat liver microsomes.LASSBio-2337 is aqueous insoluble.LASSBio-2337 can be used for the research of acute lymphoblastic leukemia, chronic myelogenous leukemia, breast cancer .
    LASSBio-2337
  • HY-P991851
    Anti-CD11c Antibody (3.9)

    		Integrin Inflammation/Immunology
    Anti-CD11c Antibody (3.9) recognizes human CD11c. Anti-CD11c Antibody (3.9) blocks CD11c on human peripheral blood mononuclear cell-derived dendritic cells (MoDCs). Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
    Anti-CD11c Antibody (3.9)
  • HY-182596
    INHIB1X

    		MAPKAPK2 (MK2) Inflammation/Immunology Cancer
    INHIB1X is a tetracyclic MAPKAP-K2 (MK2) inhibitor with an IC50 of 0.02 μM. INHIB1X inhibits LPS-induced TNFα release in human peripheral blood mononuclear cells (hPBMCs). INHIB1X suppresses the phosphorylation of hsp27 in Anisomycin-stimulated THP-1 cells. INHIB1X can be used for the research of inflammatory and tumor diseases .
    INHIB1X
  • HY-123238
    AG-024104

    		CDK Cancer
    AG-024104 is a CDK inhibitor with Ki values of 2.3 nM (CDK1/cyclinB), 1.8 nM (CDK2/cyclinA), and 0.67 nM (CDK4/cyclinD). AG-024104 functionally inhibits kinase activity of CDK1/cyclinB, CDK2/cyclinA, and CDK4/cyclinD. AG-024104 serves as a negative control for peripheral leukocyte toxicity studies in preclinical development .
    AG-024104
  • HY-125577
    VRT-18858

    RU-36384

    		 Interleukin Related Inflammation/Immunology
    VRT-18858 (RU-36384), the active metabolite of Pralnacasan (HY-19676), is a potent interleukin-1β converting enzyme (ICE) inhibitor (Ki = 1.4 nM). VRT-18858 inhibits LPS (HY-D1056)-induced IL-1β release (IC50 = 0.42 µM) and S. aureus Cowan-induced IL-1β and IL-18 release (IC50=1.3 and 2.1 µM, respectively) in human peripheral blood mononuclear cells. VRT-18858 can be used for osteoarthritis research .
    VRT-18858
  • HY-182047
    PD-1/PD-L1-IN-61

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-61 is a PD-1/PD-L1 interaction inhibitor with a human IC50 of 5.3 nM. PD-1/PD-L1-IN-61 embeds into the hydrophobic pocket at the PD-L1 dimer interface, stabilizing binding through hydrogen bonds and π-π stacking with PD-L1 residues. PD-1/PD-L1-IN-61 acts as an immune activator, enhances immune-killing activity of peripheral blood mononuclear cells against cancer cells, restores T-cell immune function, and promotes IFN-γ secretion. PD-1/PD-L1-IN-61 can be used for the research of triple-negative breast cancer .
    PD-1/PD-L1-IN-61
  • HY-P992390
    IOR-T3

    		CD3 Inflammation/Immunology
    IOR-T3 is a monoclonal antibody targeting CD3, with biological activities related to T cell activation regulation . IOR-T3 uses its variable region to competitively engage surface CD3 on lymphocytes and trigger robust T cell proliferation and activation. IOR-T3 and its derivatives can be used in studies related to acute transplant rejection .
    IOR-T3
  • HY-P992348
    DS-7011a

    		Toll-like Receptor (TLR) Inflammation/Immunology
    DS-7011a is a selective inhibitor targeting TLR7. DS-7011a inhibits IL-6 production induced by TLR7 stimulation and related responses in B cells and plasmacytoid dendritic cells. DS-7011a is internalized in a TLR7-dependent manner and accumulates in B cells, various dendritic cell subsets, and monocytes/macrophages. DS-7011a can be used in research related to systemic lupus erythematosus (SLE) .
    DS-7011a

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: